Intellia Therapeutics (NTLA) Tops Q1 EPS by 23c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.17), $0.23 better than the analyst estimate of ($1.40). Revenue for the quarter came in at $12.61 million versus the consensus estimate of $11.66 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Freedom Broker Starts Unity Bancorp (UNTY) at Hold
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank